1376514-18-9

Upstream product

• 1376607-33-8 (3S)-3-({2-amino-5-[4-(hydroxymethyl)-2-methoxybenzyl]-6-methylpyrimidin-4-yl}amino)hexan-1-ol 
• 1376607-31-6 methyl 4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzoate 
• 1376514-15-6 4-[(2-amino-4-chloro-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzonitrile 
• 1376514-14-5 4-[(2-amino-4-hydroxy-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzonitrile 
• 1376514-13-4 ethyl 2-(4-cyano-2-methoxybenzyl)-3-oxobutanoate 
• 1376514-24-7 2-amino-5-(4-cyano-2-methoxybenzyl)-6-methylpyrimidin-4-yl 2,4,6-tri(propan-2-yl)-benzenesulfonate 
• 1376514-16-7 4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzonitrile 
• 38256-93-8 N-methyl-N-(2-methoxyethyl)amine 
• 1376514-17-8 4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzaldehyde 
• 104436-60-4 4-bromomethyl-3-methoxybenzonitrile 

Downstream Products

• 1376513-98-2 2-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-5-{[(2-hydroxyethyl)(methyl)amino]methyl}phenol 
• 1376607-09-8 (3S)-3-{[2-amino-5-(4-{[(2-hydroxyethyl)(methyl)amino]methyl}-2-methoxybenzyl)-6-methylpyrimidin-4-yl]amino}hexan-1-ol 

Relevant academic research and scientific papers

PHENOL COMPOUNDS ALS TOLL -LIKE RECEPTOR 7 AGONISTS

The invention concerns compounds of Formula (I): wherein R1, R2, R3 and Q are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful

BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS

The invention concerns compounds of Formula (I), and pharmaceutically acceptable salts thereof: where such compounds act as TLR7 agonists and at the same time show advantageous selectivity over TLR8 and hERG, wherein the variable groups R1, R2 and n are as defined herein. The invention also relates to methods for the preparation of such compounds and intermediates useful in the preparation thereof, to pharmaceutical compositions containing such compounds, to the use of such compounds in the preparation of medicaments, and to the use of such compounds in the treatment of conditions mediated by TLR7, such as allergic diseases, autoimmune diseases, viral diseases and, in particular, cancer.